Thioctamer: a novel thioctic acid-glatiramer acetate nanoconjugate expedites wound healing in diabetic rats
- PMID: 35642489
- PMCID: PMC9176700
- DOI: 10.1080/10717544.2022.2081382
Thioctamer: a novel thioctic acid-glatiramer acetate nanoconjugate expedites wound healing in diabetic rats
Abstract
The current work aims to design thioctic acid (TA) and glatiramer acetate (GA) nanoconjugate (thioctamer) loaded hydrogel formula as well as evaluation of thioctamer preclinical efficacy in expediting wound healing in a rat model of the diabetic wound. Thioctamer was prepared by conjugation of GA and TA in a 1:1 molar ratio. Particle size, zeta potential, and thermodynamic stability of the prepared thioctamer were assessed. Thioctamer was loaded in hydroxypropyl methylcellulose-based hydrogel and in vitro release study was investigated. The ability of thioctamer to enhance the process of wound healing in diabetic rats was investigated by assessing wound contraction and immunohistochemical assessment of the inflammation markers IL-6 and TNF-α. The results demonstrated that thioctamer showed particle size of 137 ± 21.4 nm, polydispersity index (PDI) of 0.235, and positive zeta potential value of 7.43 ± 4.95 mV. On day 7 of making a skin excision, diabetic rat wounds administered thioctamer preparation showed almost complete healing (95.6 ± 8.6%). Meanwhile, % of wound contraction in animals treated with TA or GA groups exhibited values amounting to 56.5 ± 5.8% and 62.6 ± 7.1%, respectively. Histological investigation showed that the highest healing rate was noted in the thioctamer group animals, as the surface of the wound was nearly fully protected by regenerated epithelium with keratinization, with few inflammatory cells noticed. Thioctamer significantly (p<.05) inhibited IL-6 and TNF-α expression as compared with sections obtained from the negative control, TA, GA, or positive control group animals on day 7. The evidence of the ability of thioctamer to significantly expedite wound healing in the diabetic rats is presented.
Keywords: Alpha-lipoic acid; HPMC hydrogel; IL-6; TNF-α; diabetic wounds; nanoparticles.
Conflict of interest statement
The authors declare no conflict of interest. This work is protected under United States Patent and Trademark Office (USPTO) application number: USSN 17/681,794.
Figures
References
-
- Abdulaziz Al Dawish M, Alwin Robert A, Braham R, et al. (2016). Diabetes mellitus in Saudi Arabia: a review of the recent literature. Curr Diabetes Rev 12:1776–68. - PubMed
-
- Ahmed O, Afouna MIMI, El-Say KMKM, et al. (2014). Optimization of self-nanoemulsifying systems for the enhancement of in vivo hypoglycemic efficacy of glimepiride transdermal patches. Expert Opin Drug Deliv 11:1005–13. - PubMed
-
- Alhakamy NA, Berkland CJ. (2019). Glatiramer acetate (Copaxone) is a promising gene delivery vector. Mol Pharm 16:1596–605. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources